MedTrace Logo

Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress

NCT02904109 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-03-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of the eNOS activating agent triflusal on episodic memory and cognitive functions in participants under chronic stress.

Conditions

  • Healthy

Interventions

DRUG

Triflusal

Once daily oral administration of 600 mg triflusal Disgren® for 8 days.

DRUG

Placebo

Once daily oral administration of placebo mannitol for 8 days.

Sponsors & Collaborators

  • Prof. Dominique de Quervain, MD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-13
Primary Completion
2017-02-21
Completion
2017-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02904109 on ClinicalTrials.gov